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ABSTRACT
Steroid inhalation therapy is recommended for treat-
ment of moderate to severe asthma, but it is unknown 
whether the therapy sufficiently suppresses production
of thromboxane A2 (TXA2), one of the inflammatory 
lipid mediators. The effect of a selective orally active 
thromboxane synthesis inhibitor, ozagrel hydrochlo-
ride (200mg twice a day for 4 weeks), on morning 
and evening peak expiratory flow (PEF) was examined 
in 70 stable asthmatics receiving beclomethasone
diproprionate (BDP) inhalation therapy (800μg/day)
by a randomized, placebo-controlled, single-blinded 
study. Morning PEF was significantly increased from
313.5±13.1 (mean±SEIM) L/min to 325.7±12.2
L/min at 1 week, 335.5±12.7L/min at 2 weeks,
338.6±13.4L/min at 3 weeks, and 340.0±13.2
L/min at 4 weeks in 35 patients treated with ozagrel 
but not in the other 35 patients treated with a placebo. 
The percent increase in the morning PEF was signif-
icantly greater with ozagrel than with the placebo. It 
is speculated that inhibition of thromboxane synthesis 
by medium dose of steroid inhalation therapy may be 
insufficient in some asthmatics.
Key words: asthma, ozagrel hydrochloride, peak expi-
ratory flow, steroid inhalation therapy, thromboxane 
synthetase inhibitor.
INTRODUCTION
Steroid inhalation therapy is recommended for treatment 
of moderate to severe asthma.1 Its anti-asthma effect is 
thought to result from the production of anti-inflamma-
tory protein lipocortins, which inhibit phospholipase A22 
and prevent cell-to-cell interactions by directly inhibiting
the expression of cytokines in inflammatory cells.3 If this 
mechanism really operates, production of thromboxane 
A2 (TXA2), an arachidonic acid metabolite via cyclooxy-
genase, could be reduced with steroid inhalation therapy. 
Ozagrel hydrochloride is a newly developed thrombox-
ane synthetase inhibitor and widely used for treatment of 
asthma in Japan.4 To elucidate whether steroid inhalation 
therapy has a sufficient inhibitory effect on TXA2 produc-
tion, the effect of ozagrel on peak expiratory flow (PEF) 
was examined in stable asthmatic patients undergoing 
medium dose beclomethasone diproprionate (BDP) in-
halation therapy.
METHODS
Seventy patients with stable asthma receiving BDP inhala-
tion therapy (800μg/day) for 8 weeks or more partici-
pated in the study. Informed consent was obtained from 
all patients after the purpose of the study had been
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explained. This study was approved by the ethics commit-
tee of each hospital. 
 All patients had not suffered from an asthma attack, 
except for mild wheezing and chest tightness, while they 
had been having the BDP inhalation therapy, oral theo-
phylline and/or oral β2 -agonist regularly, and/or aerosol
β2-agonists as needed. Each patient recorded morning
and evening PEF measurements using the ASSESS(R) peak 
flow meter (Health Scan Products Inc., Cedar Grove, NJ, 
USA) in his or her asthma diary every day. Each patient 
ensured that PEF was measured before the 'rescue' use of
inhaled β2-agonists.Eiach PEF measurementwas per-
formed in triplicate and the best value was recorded each 
time. The patients were randomly divided into two groups 
according to their identity number (an odd number for 
ozagrel and an even number for the placebo or vice
versa) that was determined for each hospital at the pre-
liminary meeting. Thirty-five patients were treated with 
ozagrel (200 mg twice a day) and 35 with placebo tablets 
(1 tablet twice a day) for 4 weeks, after a 4 week trial 
period using a single-blind method. Concomitant medi-
cation was maintained without any modification during 
the study period.
 The mean value of the morning or evening PEF mea-
surements every week was calculated in each patient and 
used for data analysis. The morning and evening PEF val-
ues were compared between the trial and the treatment 
periods in each group using the Wilcoxon signed rank
test. The percent increase in the PEF value with the treat-
ment from the mean PEF value during the 2-week trial 
period before the treatment was compared between the 
two groups using the Mann-Whitney U-test. The differ-
ence with a P value of 0.05 or less was considered statis-
tically significant.
RESULTS
Clinical characteristics and pulmonary function during 
the trial period for the ozagrel and placebo groups are 
shown in Tables 1 and 2, respectively. No patient had 
taken oral steroids. Severity of asthma was moderate in
most patients of the two groups. Other patient character-
istics were not different between the two groups. Baseline 
pulmonary function, including PEF, did not differ between 
the two groups.
  Morning PEF was significantly increased from 313.5±
13.1 (mean±SEM) L/min to 325.7±12.2L/min at 
week, 335.5±12.7L/min at 2 weeks,338.6±13.4
L/min at 3 weeks, and 340.0±13.2L/min at 4 weeks in
patients given ozagrel. The value was not altered in
patients receiving the placebo (317.6±17.3L/min
before treatment,316.9±17.0L/min at 1 week, 317.3
±16.4L/min at 2 weeks, 319.3±16.7L/min at 3
weeks, and 318.7±16.7L/min at 4 weeks). Evening
PEF was also significantly increased with ozagrel but not 
with the placebo.
 The percent increases in morning PEF from the pre-
treatment value are shown in Fig. 1. The values were sig-
nificantly greater in patients treated with ozagrel than in
patients treated with the placebo (12.5±3.3% vs 0.1±
2.9% at 1 week, 22.3±5.0% vs 0.5±4.0% at 2 weeks,
25.3±5.3% vs 2.6±3.7% at 3 weeks, and 26.7±
5.2% vs 1.9±3.8% at 4 weeks).
Table 1. Clinical characteristics of the 70 study patients
Table 2. Baseline pulmonary function of the 70 study patients
(mean±SD)
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Fig. 1 Mean values (± SEM) for percent increases in morning
peak expiratory flow rate (PEF) by treatment with a thromboxane 
synthesis inhibitor (ozagrel hydrochloride) or placebo in asth-
matic patients undergoing beclomethasone inhalation therapy
(800μg/day) for 8 weeks or more. *P values for differences
between groups treated with ozagrel hydrochloride and
placebo analyzed by the Mann-Whitney U-test. (-〇-) Treat-
ment with ozagrel hydrochloride (n=35), (-●-) treatment with
placebo (n=35).
 The percent increases in evening PEF were also signifi-
cantly greater with ozagrel than with the placebo from 1 
week to 4 week (Fig. 2).
 Spirometry was performed in 26 patients in the 4th 
week of treatment with ozagrel and in 18 patients with 
placebo. Forced expiratory volumes in 1 s (FEV,) tended
to increase from 1.69 ± 0.64 to 1.79±0.67L (P=
0.078) with ozagrel but did not change with the placebo
(from 1.64±0.39 to 1.70±0.45L). FVC did not
increase with either ozagrel or placebo.
 No adverse effects were recognized with ozagrel or 
placebo.
DISCUSSION
Our study presented here showed that morning and 
evening PEF were increased by oral administration of a 
TXA2 synthetase inhibitor, ozagrel, in stable asthmatic
patients receiving inhalation therapy of 800μg/day of
BDR These results indicate that the medium dose of
Fig. 2 Mean values (± SEM) for percent increases in evening
peak expiratory flow rate (PEF) by treatment with a thromboxane 
synthesis inhibitor (ozagrel hydrochloride) or placebo in asth-
matic patients undergoing beclomethasone inhalation therapy
(800μg/day) for 8 weeks or more. *P values for differences
between groups treated with ozagrel hydrochloride and
pl cebo analyzed by the Mann-Whitney U-test.(-〇-)Treat-
ment wi h ozagrel hydrochloride (n=35), (-●-) treatment with
placebo (n=35).
inhaled BDP may be insufficient to inhibit TXA2 production 
in so e asthmatics. Two explanations are likely for why 
ozagrel increased PEF in the patients undergoing BDP
inhalation therapy. One is that 800μg/day of inhaled
BDP has no, or only a weak, inhibitory effect on TXA2 syn-
thesis via the production of lipocortins, and the other is 
that systemically administered ozagrel might inhibit TXA2 
synthesis in the airways that have not received inhaled 
steroids because the distribution of inhaled BDP to air-
ways may be uneven because of an insufficient control of 
asthma. Tamura showed that an orally active selective 
leukotriene D4 receptor antagonist, ONO-1078, in-
creased morning and evening PEF in 10 patients with
asthma receiving 1000μg/day of BDP inhalation ther-
apy in a double-blinded, placebo-controlled, cross-over 
study.5 Taking these results together, it is suggested that 
steroid inhalation therapy at medium doses may be insuf-
ficient to suppress production of inflammatory lipid medi-
ators in asthma.
As our primary end-point in this study was to assess the
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effect of ozagrel on morning and evening PEF in stable 
asthmatics undergoing inhalation of medium dose BDP, 
we did not analyze asthma symptoms or dose used of
inhaled β2-agonists, although symptoms such as wheez-
ing and chest tightness were recognized in nearly one-
quarter of patients in each group. Further controlled 
studies are needed in which the effects of TXA2 inhibitors
on asthma symptoms, use of inhaled β2-agonists and PEF
are examined in symptomatic or severe asthmatics who 
are taking inhalation therapy with medium or high dose 
of steroids.
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